Table 3.

Crude and adjusted hazard ratios with confidence intervals from a Cox model after multiple imputation for all HIV-infected deaths during TB treatment

	Crude		Adjusted		Adjusted (selected by AIC*)
	HR (95 % CI)	p value	HR (95 % CI)	p value	HR (95 % CI)
Sex female	0.98 (0.85–1.14)	0.84	1.24 (1.06–1.45)	0.01	1.23 (1.06–1.44)
Age
<25	Reference		Reference		Reference
25–35	1.25 (0.92–1.68)	0.15	1.24 (0.92–1.68)	0.17	1.25 (0.92–1.70)
35–45	1.58 (1.16–2.14)	0.00	1.60 (1.17–2.18)	0.00	1.62 (1.19–2.21)
45–60	2.39 (1.73–3.29)	0.00	2.50 (1.80–3.46)	0.00	2.54 (1.83–3.52)
>60	4.72 (2.99–7.44)	0.00	4.79 (3.00–7.65)	0.00	4.80 (3.00–7.66)
Anatomic site of TB
Pulmonary	Reference		Reference
Extra-pulmonary	1.16 (0.98–1.38)	0.09	1.14 (0.93–1.41)	0.21
Both	1.44 (1.12–1.85)	0.01	1.29 (1.00–1.68)	0.05
Prior TB	1.12 (0.95–1.32)	0.18	1.16 (0.98–1.37)	0.09
TB smear result
Smear negative	Reference		Reference
Smear positive	0.98 (0.83–1.16)	0.83	1.07 (0.89–1.28)	0.47
No smear performed	1.16 (0.93–1.45)	0.18	1.08 (0.85–1.36)	0.54
CD4 count
<50	Reference		Reference		Reference
50–100	0.79 (0.61–1.02)	0.07	0.79 (0.60–1.02)	0.07	0.78 (0.60–1.01)
100–200	0.55 (0.41–0.75)	0.00	0.54 (0.40–0.71)	0.00	0.53 (0.40–0.71)
200–350	0.47 (0.37–0.61)	0.00	0.43 (0.34–0.56)	0.00	0.43 (0.33–0.55)
350+	0.28 (0.18–0.43)	0.00	0.24 (0.16–0.37)	0.00	0.24 (0.16–0.37)
TMP-SMX chemoprophylaxis	1.01 (0.69–1.46)	0.96	0.88 (0.60–1.29)	0.52
ART during TB treatment	0.76 (0.64–0.91)	0.00	0.60 (0.50–0.72)	0.00	0.61 (0.51–0.73)

TB tuberculosis, ART antiretroviral treatment, TMP-SMX trimethoprim sulfamethoxazole 160/80 mg chemoprophylaxis, HR hazard ratio, 95 % CI 95 % confidence interval, AIC Akaike information criterion